Samsung Biologics Launches a $1.8 Billion All Cash Bid to Acquire PolyPeptide
Samsung Biologics said on Thursday it has made an all-cash bid of $1.81 billion to buy Swiss pharma manufacturer PolyPeptide, one of its greatest drives to grow worldwide. The transaction is meant to strengthen Samsung’s position in the rapidly expanding market for peptide therapeutics, including treatments for obesity and diabetes. The projected purchase also shows an increasing degree of concentration in the global contract medicines manufacturing industry.
Samsung Targets Fast-Growing Peptide Drug Market
Samsung Biologics said it will pay 44.31 Swiss francs per share for the proposed transaction, valuing PolyPeptide at around 1.46 billion Swiss francs ($1.81 billion). The offer is a 6.1 percent premium to PolyPeptide’s last closing share price of 41.75 Swiss francs.
The tender offer is expected to open by the end of August 2026 and to be completed before year-end, subject to regulatory approvals and shareholder acceptance conditions. Samsung said the deal was in accordance with its long-term goal to diversify into peptide-based drug manufacturing beyond biologics, a sector that is witnessing high demand due to GLP-1 drugs.
Moonshot Plans IPO Within Six Months After Its China AI Breakthrough Gains Global AttentionGrowth strategy, not financial performance
This is an announcement about a strategic acquisition, not quarterly profits. Samsung Biologics did not provide new figures for revenue, profit, EPS, dividend or share repurchase related to the deal.
Rather, the firm highlighted the synergies between PolyPeptide’s peptide production capabilities and Samsung’s global CDMO platform, which will increase the company’s products across a number of therapeutic areas. The acquisition gives Samsung a larger worldwide manufacturing network with production locations in Europe, the United States and India, PolyPeptide said.
Investor sees shareholder support, regulatory process
Support for the possible deal is already strong. PolyPeptide’s independent directors unanimously recommended shareholders to accept the offer and its major stakeholder Draupnir Holding, which owns roughly 55.65% of the company, agreed to tender its shares.
Samsung will purchase the remaining minority stake post-closing and list PolyPeptide as a wholly owned subsidiary on the SIX Swiss Exchange. The deal is part of ongoing investment in high-growth areas of pharmaceutical manufacturing as demand for peptide-based medicines grows globally.
What this means for investors
The transaction also strengthens Samsung Biologics’ competitiveness in contract pharmaceutical manufacturing with its specialist peptide manufacturing capabilities. The move also adds to the company’s manufacturing portfolio as pharmaceutical companies ramp up the outsourcing of advanced medications.
Investors will watch to see if the combination brings in new manufacturing contracts and supports long-term revenue growth. The key near-term milestones are the attainment of regulatory approvals and the successful closure of the tender offer.
What’s Coming Up?
Samsung expects to launch the public tender offer by the end of August 2026 and aims to complete it by the end of the year pending satisfaction of all conditions. The deal is subject to regulatory approvals and enough participation by shareholders. Upon closing, PolyPeptide will join Samsung Biologics’ global CDMO business to expand its footprint in the peptide therapies space and provide a platform for future growth in obesity, diabetes and other speciality medicines.
Sources
PR Newswire
Official acquisition announcement, offer price of CHF 44.31 per share, equity value of CHF 1.46 billion, plan to acquire 100% shares, conditions for regulatory approval, and Samsung’s strategy to expand its multi-modality CDMO.
MarketScreener
Stock reaction of Samsung Biologics and PolyPeptide Deal valuation information How the 6.1% premium was calculated Transaction timing How investors reacted following the announcement
SIX Swiss Exchange
PolyPeptide tender offer procedure, projected offer period, conditions for shareholder approval and delisting process upon completion.
Samsung
Company growth plan, expansion of manufacturing capabilities, focus on peptide-based active pharmaceutical ingredients (APIs), and long-term worldwide CDMO targets.
Investing.com
Samsung Biologics stock reaction following announcement, market response, implications of the deal for healthcare investors and how it compares to the wider KOSPI.
